Kartik Singhal

Program: Molecular Genetics and Genomics

Current advisor: Malachi Griffith, PhD

Undergraduate university: University of California-Davis, 2018

Enrollment year: 2021

Research summary
Integrates multi-omic analyses and immune profiling to stratify lymphoma patients by CAR-T response and advance neoantigen-based immunotherapies through vaccine design and TCR-seq–guided discovery of antigen-specific T cells.

Kartik Singhal’s research integrates multi-omic and immunogenomic approaches to understand tumor-immune interactions and improve personalized cancer immunotherapies. His work stratifies over 200 Large B-cell lymphoma patients by CAR-T therapy response using single-nuclei multiome-seq, whole exome, whole genome, and bulk RNA-seq data. In parallel, he contributes to multiple clinical trials by executing computational neoantigen prediction pipelines, identifying candidate neoantigens, and supporting personalized vaccine design. To further enhance neoantigen-based therapies, he developed novel analytical frameworks integrating bulk and single-cell RNA and TCR sequencing data to identify and characterize neoantigen-specific T cells. Together, these efforts aim to bridge systems-level tumor profiling with functional immunology to advance precision oncology.

Graduate publications
Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. 2025 Large B cell lymphoma microenvironment archetype profiles. Cancer Cell, 43(7):1347-1364.e13. PMCID: PMC12417684

Ramirez CA, Becker-Hapak M, Singhal K, Russler-Germain DA, Frenkel F, Barnell EK, McClain E, Desai S, Schappe T, Onyeador OC, Kudryashova O, Belousov V, Bagaev A, Ocheredko E, Kiwala S, Hundal J, Skidmore ZL, Watkins MP, Mooney TB, Walker J, Krysiak K, Gomez F, Fronick CC, Fulton RS, Schreiber RD, Mehta-Shah N, Cashen AF, Kahl BS, Ataullakhanov R, Bartlett NL, Griffith M, Griffith OL, Fehniger TA. 2024 Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma. Blood Adv, 8(15):4035-49. PMCID: PMC11339042

Krysiak K, Danos AM, Saliba J, McMichael JF, Coffman AC, Kiwala S, Barnell EK, Sheta L, Grisdale CJ, Kujan L, Pema S, Lever J, Ridd S, Spies NC, Andric V, Chiorean A, Rieke DT, Clark KA, Reisle C, Venigalla AC, Evans M, Jani P, Takahashi H, Suda A, Horak P, Ritter DI, Zhou X, Ainscough BJ, Delong S, Kesserwan C, Lamping M, Shen H, Marr AR, Hoang MH, Singhal K, Khanfar M, Li BV, Lin WH, Terraf P, Corson LB, Salama Y, Campbell KM, Farncombe KM, Ji J, Zhao X, Xu X, Kanagal-Shamanna R, King I, Cotto KC, Skidmore ZL, Walker JR, Zhang J, Milosavljevic A, Patel RY, Giles RH, Kim RH, Schriml LM, Mardis ER, Jones SJM, Raca G, Rao S, Madhavan S, Wagner AH, Griffith M, Griffith OL. 2023 CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase. Nucleic Acids Res, 51(D1):D1230-D1241. PMCID: PMC9825608

Singhal K, Watkins MP, Fehniger TA, Griffith MG, Griffith OL, Kahl BS, Russler-Germain DA. 2023 Donor-Derived Follicular Lymphoma After Kidney Transplantation: A Case Report. JCO Precis Oncol, 7():e2300177. PMCID: